Hormone replacement therapy and sensitive C-reactive protein concentrations in women with type-2 diabetes.
C-reactive protein concentrations as a marker of inflammation predicts vascular risk and is raised in type-2 diabetes. In a 6-month double-blind placebo controlled trial, a combination of transdermal oestradiol 80 microg with continuous oral norethisterone 1 mg significantly reduced C-reactive protein concentrations in postmenopausal women with type-2 diabetes.
Sattar
N
N
Perera
M
M
Small
M
M
Lumsden
M A
MA
D000368:Aged; D002097:C-Reactive Protein / Q000378:metabolism*; D015331:Cohort Studies; D003324:Coronary Artery Disease / Q000097:blood / Q000517:prevention & control; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D004311:Double-Blind Method; D015914:Estrogen Replacement Therapy; D005260:Female; D006801:Humans; D008875:Middle Aged
D002097:C-Reactive Protein